BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12365012)

  • 1. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
    Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
    Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
    Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
    Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
    Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
    Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.
    Birner P; Oberhuber G; Stani J; Reithofer C; Samonigg H; Hausmaninger H; Kubista E; Kwasny W; Kandioler-Eckersberger D; Gnant M; Jakesz R;
    Clin Cancer Res; 2001 Jun; 7(6):1669-75. PubMed ID: 11410505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.
    Osman I; Scher HI; Drobnjak M; Verbel D; Morris M; Agus D; Ross JS; Cordon-Cardo C
    Clin Cancer Res; 2001 Sep; 7(9):2643-7. PubMed ID: 11555574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma.
    Hoang MP; Sahin AA; Ordòñez NG; Sneige N
    Am J Clin Pathol; 2000 Jun; 113(6):852-9. PubMed ID: 10874886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
    Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization.
    Rossi E; Villanacci V; Bassotti G; Casa DD; Missale G; Minelli L; Cestari R
    Diagn Mol Pathol; 2006 Sep; 15(3):125-30. PubMed ID: 16932066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
    Coogan CL; Estrada CR; Kapur S; Bloom KJ
    Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
    Minner S; Jessen B; Stiedenroth L; Burandt E; Köllermann J; Mirlacher M; Erbersdobler A; Eichelberg C; Fisch M; Brümmendorf TH; Bokemeyer C; Simon R; Steuber T; Graefen M; Huland H; Sauter G; Schlomm T
    Clin Cancer Res; 2010 Mar; 16(5):1553-60. PubMed ID: 20179235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
    Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
    Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her-2/neu expression in prostate cancer: a dynamic process?
    Carles J; Lloreta J; Salido M; Font A; Suarez M; Baena V; Nogue M; Domenech M; Fabregat X
    Clin Cancer Res; 2004 Jul; 10(14):4742-5. PubMed ID: 15269147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM; Murren JR; Rimm DL; King BL
    Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
    Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
    Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of HER-2/neu expression in germ-cell testicular tumors.
    Mándoky L; Géczi L; Bodrogi I; Tóth J; Csuka O; Kásler M; Bak M
    Anticancer Res; 2004; 24(4):2219-24. PubMed ID: 15330164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.